Takeda Prices Oral Multiple Myeloma Follow-On Ninlaro On Par With Velcade
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of the next-generation proteasome inhibitor ixazomib will pave the way for an all-oral combination with Revlimid and dexamethasone and give Takeda an opportunity to extend its oncology franchise beyond Velcade, which could see generic competition in late 2017.
You may also be interested in...
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.